Latest & greatest articles for fluticasone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluticasone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluticasone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluticasone

41. Cohort study: Inhaled fluticasone and budesonide increased the risk of serious pneumonia in COPD

Cohort study: Inhaled fluticasone and budesonide increased the risk of serious pneumonia in COPD Inhaled fluticasone and budesonide increased the risk of serious pneumonia in COPD | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Inhaled fluticasone and budesonide increased the risk of serious pneumonia in COPD Article Text Harm Cohort study Inhaled fluticasone and budesonide increased the risk of serious pneumonia in COPD Patrick White

2014 Evidence-Based Medicine (Requires free registration)

42. Revinty Ellipta - fluticasone furoate / vilanterol

Revinty Ellipta - fluticasone furoate / vilanterol 20 March 2014 EMA/CHMP/175905/2014 Committee for Medicinal Products for Human Use (CHMP) Assessment report Revinty Ellipta International non-proprietary name: fluticasone furoate / vilanterol Procedure No. EMEA/H/C/002745/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union (...) Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail info@ema.europa.eu Website www.ema.europa.eu © European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. Product information Name of the medicinal product: Revinty Ellipta Applicant: Glaxo Group Ltd Glaxo Group Ltd 980 Great West Road Brentford Middlesex TW8 9GS United Kingdom Active substance: Fluticasone furoate / vilanterol trifenatate International Nonproprietary Name Fluticasone furoate

2014 European Medicines Agency - EPARs

43. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial (PubMed)

Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial The inhaled corticosteroid fluticasone furoate (FF) in combination with the long-acting β2 agonist vilanterol (VI) is in development for asthma and chronic obstructive pulmonary disease.To assess the safety and tolerability of FF/VI over 52 weeks in patients (...) with asthma.Patients (aged ≥12 years; on inhaled corticosteroid) were randomised (2:2:1) to FF/VI 100/25 µg or FF/VI 200/25 µg once daily in the evening, or fluticasone propionate (FP) 500 µg twice daily. Safety evaluations included adverse events (AEs), non-fasting glucose, potassium, 24-h urinary cortisol excretion, ophthalmic assessments, heart rate and pulse rate.On-treatment AEs were similar across groups (FF/VI 66-69%; 73% FP). Oral candidiasis/oropharyngeal candidiasis was more common with FF/VI (6-7%) than

Full Text available with Trip Pro

2013 EvidenceUpdates

44. Randomized Controlled Trial Comparing Aerosolized Swallowed Fluticasone to Esomeprazole for Esophageal Eosinophilia (PubMed)

Randomized Controlled Trial Comparing Aerosolized Swallowed Fluticasone to Esomeprazole for Esophageal Eosinophilia Patients with clinical symptoms of esophageal dysfunction and dense eosinophilic infiltration of the esophageal mucosa are suspected to have eosinophilic esophagitis (EoE). Topical steroids are often used as first-line therapy for EoE, although some patients respond clinically to proton pump inhibitors (PPIs). The purpose of this study was to compare the histological and clinical (...) response of patients with esophageal eosinophilia treated with aerosolized swallowed fluticasone propionate vs. esomeprazole.This prospective single-blinded randomized controlled trial enrolled newly diagnosed patients with suspected EoE, defined as having clinical symptoms related to esophageal dysfunction with at least 15 eosinophils/high power field (hpf). Patients underwent 24-h pH/impedance monitoring to establish gastroesophageal reflux disease (GERD). Patients were stratified by the presence

2013 EvidenceUpdates

45. Chronic obstructive pulmonary disease: fluticasone furoate plus vilanterol

Chronic obstructive pulmonary disease: fluticasone furoate plus vilanterol Chronic obstructiv Chronic obstructive pulmonary disease: e pulmonary disease: fluticasone furoate plus vilanterol fluticasone furoate plus vilanterol Evidence summary Published: 18 June 2013 nice.org.uk/guidance/esnm21 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in June 2013. See summaries of product characteristics (SPCs), British national (...) formulary (BNF) or the MHRA or NICE websites for up- to-date information. Summary Fluticasone furoate/vilanterol (Relvar Ellipta) is a once-daily corticosteroid and long-acting beta 2 agonist combination inhaler, which has been submitted for a marketing authorisation for the symptomatic treatment of adults with chronic obstructive pulmonary disease (COPD) and an exacerbation history despite regular bronchodilator therapy. There are currently no published studies comparing fluticasone furoate/vilanterol

2013 National Institute for Health and Clinical Excellence - Advice

46. Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) - For the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema

Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) - For the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Ellipta (fluticasone furoate and vilanterol trifenatate) Inhalation Powder Company: GlaxoSmithKline

2013 FDA - Drug Approval Package

47. Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma

Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma Gerzeli S, Rognoni C, Quaglini S, Cavallo MC (...) , Cremonesi G, Papi A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of beclomethasone with formoterol versus fluticasone propionate with salmeterol, for patients with moderate-to-severe

2013 NHS Economic Evaluation Database.

48. Relvar Ellipta - fluticasone furoate / vilanterol

Relvar Ellipta - fluticasone furoate / vilanterol 19 September 2013 EMA/282960/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Relvar Ellipta International non-proprietary name: fluticasone furoate / vilanterol Procedure No. EMEA/H/C/002673/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone (...) +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail info@ema.europa.eu Website www.ema.europa.eu © European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. Product information Name of the medicinal product: Relvar Ellipta Applicant: Glaxo Group Ltd 980 Great West Road Brentford Middlesex TW8 9GS United Kingdom Active substance: Fluticasone furoate / vilanterol trifenatate International Nonproprietary Names: Fluticasone furoate / vilanterol Pharmaco

2013 European Medicines Agency - EPARs

49. Asthma: fluticasone/formoterol (Flutiform) combination inhaler

Asthma: fluticasone/formoterol (Flutiform) combination inhaler Asthma: fluticasone/formoterol (Flutiform) Asthma: fluticasone/formoterol (Flutiform) combination inhaler combination inhaler Evidence summary Published: 12 October 2012 nice.org.uk/guidance/esnm3 pathways Ov Overview erview Key points from the evidence The content of this evidence summary was up-to-date in October 2012. See summaries of product characteristics (SPCs), British national formulary (BNF), BNF for children (BNFc (...) ) or the MHRA or NICE websites for up-to-date information. Fluticasone/formoterol (Flutiform) is a combination inhaler containing an inhaled corticosteroid (ICS) and a long-acting beta-2 agonist (LABA). It was launched in the UK in September 2012 and is indicated for regular treatment of asthma when a combination inhaler is appropriate: for people whose asthma is not adequately controlled on an ICS and an 'as required' inhaled short-acting beta-2 agonist, or for people whose asthma is adequately controlled

2012 National Institute for Health and Clinical Excellence - Advice

50. Fluticasone furoate and Vilanterol (Breo Ellipta)

Fluticasone furoate and Vilanterol (Breo Ellipta) CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 204275Orig1s000 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 204275 Priority or Standard Standard Submit Date(s) July 11, 2012 Received Date(s) July 12, 2012 PDUFA Goal Date May 12, 2012 Division / Office ODEII/DPARP Reviewer Name(s) Sofia Chaudhry, MD Review Completion Date March 18, 2013 Established Name Fluticasone furoate and Vilanterol (Proposed (...) ) Trade Name Breo Ellipta Therapeutic Class ICS/LABA Applicant GlaxoSmithKline Formulation(s) Orally inhaled Dosing Regimen Once daily Indication(s) 1) Maintenance treatment of airflow obstruction 2) Reduction in exacerbation Intended Population(s) COPD Template Version: March 6, 2009 Reference ID: 3277679Clinical Review Sofia Chaudhry, MD NDA 204275 Breo Ellipta (fluticasone furoate and vilanterol) 2 Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT 9 1.1 Recommendation on Regulatory Action

2012 FDA - Drug Approval Package

51. Dymista (azelastine hydrochloride and fluticasone proprionate) Nasal Spray

Dymista (azelastine hydrochloride and fluticasone proprionate) Nasal Spray Drug Approval Package: Dymista (azelastine hydrochloride and fluticasone proprionate) NDA #202236 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Dymista (azelastine hydrochloride and fluticasone proprionate) Nasal Spray, 137 mcg/50mcg Company: Meda Pharmaceuticals, Inc. Application No.: 202236 Approval Date: 05/01/2012 Persons with disabilities having problems accessing the PDF

2012 FDA - Drug Approval Package

52. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials (PubMed)

Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials This analysis was designed to provide a comparison between budesonide/formoterol and salmeterol/fluticasone for the relative incidence of pneumonia adverse events, pneumonia serious adverse events and pneumonia-related mortality in patients being treated for chronic obstructive pulmonary disease.An initial literature search revealed (...) no suitable head-to-head trials between budesonide/formoterol and salmeterol/fluticasone and therefore a systematic review was conducted to find randomised controlled trials providing data for input into an adjusted indirect comparison of the two combination treatments using placebo as a common comparator. The Bucher adjusted indirect comparison method was used to calculate odds ratios and 95% confidence intervals.Eight salmeterol/fluticasone trials and four budesonide/formoterol trials were identified

2011 EvidenceUpdates

53. Fluticasone furoate versus fluticasone propionate for seasonal allergic rhinitis: a review of the clinical and cost-effectiveness

Fluticasone furoate versus fluticasone propionate for seasonal allergic rhinitis: a review of the clinical and cost-effectiveness Fluticasone furoate versus fluticasone propionate for seasonal allergic rhinitis: a review of the clinical and cost-effectiveness Fluticasone furoate versus fluticasone propionate for seasonal allergic rhinitis: a review of the clinical and cost-effectiveness Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Fluticasone furoate versus fluticasone propionate for seasonal allergic rhinitis: a review of the clinical and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2011 Authors' conclusions Two randomized controlled studies showed similar efficacy between

2011 Health Technology Assessment (HTA) Database.

54. Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis (PubMed)

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis In clinical trials, only about 60% of subjects report an excellent response to intranasal steroids, suggesting a need to add therapies to intranasal steroids to provide additional efficacy.To determine whether the combination of fluticasone furoate and oxymetazoline is more efficacious than either agent alone, and to determine whether rhinitis medicamentosa develops after treatment.We (...) performed a double-blind, double-dummy, randomized, placebo-controlled parallel study. Sixty patients with perennial allergy were randomized to 4 weeks of once-a-night treatment with fluticasone furoate, oxymetazoline hydrochloride, the combination, or placebo. They were monitored during treatment and for 2 weeks posttreatment.The total nasal symptom score over the 4 weeks of treatment was lower with the combination (median, 143; range, 30-316) compared with treatment with placebo (262; 116-358

2011 EvidenceUpdates

55. Comparison of the effect of low-dose ciclesonide and fixed-dose fluticasone propionate and salmeterol combination on long-term asthma control (PubMed)

Comparison of the effect of low-dose ciclesonide and fixed-dose fluticasone propionate and salmeterol combination on long-term asthma control Patients with mild persistent asthma constitute about 70% of the asthma population; thus, it is important to know which first-line treatment is best for the management of mild asthma. We compared benefits of first-line treatment with ciclesonide and a combination of fluticasone and salmeterol in patients with mild asthma.Patients aged 12 to 75 years (...) with mild persistent asthma were enrolled in a randomized, double-blind, placebo-controlled study. After run-in, patients were randomized to ciclesonide 160 μg once daily (CIC160), fluticasone propionate/salmeterol 100/50 μg bid (FP200/S100), or placebo for 52 weeks. The primary variable was time to first severe asthma exacerbation; the coprimary variable was the percentage of poorly controlled asthma days. Patients recorded asthma symptoms and salbutamol use in electronic diaries and completed

2011 EvidenceUpdates

56. Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease

Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy (...) for chronic obstructive pulmonary disease Dalal AA, Roberts MH, Petersen HV, Blanchette CM, Mapel DW Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of initial maintenance therapy with fluticasone

Full Text available with Trip Pro

2011 NHS Economic Evaluation Database.

57. Efficacy of fluticasone furoate nasal spray vs. placebo for the treatment of ocular and nasal symptoms of allergic rhinitis: a systematic review

Efficacy of fluticasone furoate nasal spray vs. placebo for the treatment of ocular and nasal symptoms of allergic rhinitis: a systematic review Efficacy of fluticasone furoate nasal spray vs. placebo for the treatment of ocular and nasal symptoms of allergic rhinitis: a systematic review Efficacy of fluticasone furoate nasal spray vs. placebo for the treatment of ocular and nasal symptoms of allergic rhinitis: a systematic review Rodrigo GJ, Neffen H CRD summary The authors concluded (...) that intranasal fluticasone furoate at a dose of 110mcg once daily was effective in improving ocular and nasal symptoms in adolescents and adults with allergic rhinitis. The authors’ conclusions reflect the evidence presented, but it should be noted that not all outcomes appeared to demonstrate clinical significance. Authors' objectives To evaluate the effectiveness of fluticasone furoate nasal spray versus placebo for the treatment of ocular and nasal symptoms in patients with allergic rhinitis. Searching

2011 DARE.

58. Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma (PubMed)

Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma For children with symptomatic asthma despite low to moderate doses of inhaled corticosteroids, evidence is still lacking whether to add a long-acting bronchodilator or to increase the dose of inhaled corticosteroids.To evaluate whether salmeterol/fluticasone propionate (SFP), 50/100 μg twice a day, is noninferior regarding symptom control compared with fluticasone propionate (FP), 200 μg twice

2011 EvidenceUpdates

59. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials

Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials Budesonide/formoterol vs salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials Budesonide/formoterol vs salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials Halpin DM, Gray J, Edwards SJ (...) , Morais J, Singh D CRD summary The review of indirect comparisons concluded that budesonide/formoterol was associated with fewer pneumonia events than salmeterol/fluticasone in patients with chronic obstructive pulmonary disease. The authors' conclusions seem reasonable but reporting limitations mean that cautious interpretation is warranted. Authors' objectives To compare the efficacy of budesonide/formoterol with salmeterol/fluticasone on the incidence of pneumonia adverse events, pneumonia serious

2011 DARE.

60. Comparative efficacy of indacaterol 150mug and 300mug versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease: a network meta-analysis

Comparative efficacy of indacaterol 150mug and 300mug versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease: a network meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.